Eledon Pharmaceuticals, Inc. (ELDN) vs Protalix BioTherapeutics, Inc. (PLX)

Eledon Pharmaceuticals, Inc. and Protalix BioTherapeutics, Inc. are both Biotechnology companies. Eledon Pharmaceuticals, Inc. and Protalix BioTherapeutics, Inc. are of similar size ($228.3M and $221.6M). Eledon Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Protalix BioTherapeutics, Inc. trades at 11.3×. Protalix BioTherapeutics, Inc. has the higher net margin (23.5% vs 0.00%) and the higher return on invested capital (48.5% vs 0.00%). Across the 13 metrics below, Protalix BioTherapeutics, Inc. leads on 10 and Eledon Pharmaceuticals, Inc. on 3.

Valuation

Metric ELDN PLX Biotechnology median
P/E n/m 11.33 7.88
P/S n/m 2.70 11.47
P/B 9.16 3.05 2.52
Price to free cash flow n/m 28.37 21.16
EV/EBITDA n/m 7.27 0.74
EV/Sales n/m 2.24 10.73
Earnings yield (34.21%) 8.82% (28.84%)
Free cash flow yield (24.43%) 3.52% (23.03%)

Profitability

Metric ELDN PLX Biotechnology median
Gross margin 0.00% 69.20% 65.16%
Operating margin 0.00% 28.89% 0.00%
Net margin 0.00% 23.50% 0.00%
Free cash flow margin 0.00% 9.51% 0.00%
Return on equity (236.51%) 31.23% (57.72%)
Return on assets (72.74%) 20.07% (49.22%)
Return on invested capital 0.00% 48.48% 0.00%

Growth

Metric ELDN PLX Biotechnology median
Revenue growth (TTM) — 30.14% 5.64%
EPS growth (last fiscal year) 30.67% (300.00%) —
Revenue growth, 5-year CAGR — (3.46%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ELDN PLX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.90 2.94 4.73
Net debt to EBITDA 1.60 7.68 0.96

Dividend

Metric ELDN PLX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ELDN PLX Biotechnology median
Market cap 228.34m 221.57m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack